CALOTATUG GINISTINAG
UNII RA7UQ7N2QE

Substance Identification & Data

This profile provides standardized clinical and technical data for Calotatug Ginistinag, uniquely identified by the FDA Unique Ingredient Identifier (UNII) RA7UQ7N2QE.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2847102-44-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

RA7UQ7N2QE

CAS Registry Number

2847102-44-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

CALOTATUG GINISTINAG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C190297

National Cancer Institute reference terminology for clinical and research data.

INN ID

12945

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Calotatug Ginistinag

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Calotatug Ginistinag. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Calotatug Ginistinag

Common Names & Synonyms

Calotatug ginistinag [WHO-DD]

H-gamma1 heavy chain Homo sapiens (1-446) [VH (Homo sapiens IGHV3-48*01 (100%) -(IGHD) -IGHJ2*01 (100%), CDR-IMGT [8.8.10] (26-33.51-58.97-106)) (1-117) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (214) (118-215), hinge 1-15 (216-230), CH2 (231-340), CH3 D12 (356), L14 (358) (341-445), CHS K2>del (446)) (118-446)], (220-215')-disulfide with L-kappa light chain Homo sapiens (1'-215') [V-KAPPA (Homo sapiens IGKV3-20*01 (97.9%) -IGKJ4*01 (100%), CDR-IMGT [7.3.9] (27'-33'.51'-53'.90'-98')) (1'-108') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (154'), V101 (192') (109'-215')]; dimer (226-226'':229-229'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1SV, glycoform alfa; substituted at the sulfur atom of eight L-cysteinyl residues at position 220, 226, 229, 215', 220'', 226'', 229'' and 215''' with radical group (3RS)-1-[(4S,47S,53S,54R,55R,56R)-4-[(15S)-20-{[(6E)-46,95-dicarbamoyl-14,124-diethyl-12,122-dimethyl-2,11-dioxo-3,10-diaza-1,12(5)-bis[1,3]oxazola-4(2,3)-imidazo[4,5-b]pyridina-9(1,2)-[1,3]benzimidazoladodecaphan-6-en-97-yl]oxy}-15-methyl-3,13,16-trioxo-7,10,17-trioxa-4,14-diazaicosan-1-yl]-53,54,55,56,57-pentahydroxy-2,5,8,11,14,17,45,50-octaoxo-47-{[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]carbamoyl}-21,24,27,30,33,36,39,42-octaoxa-3,6,9,12,15,18,46,51-octaazaheptapentacontan-1-yl]-2,5-dioxopyrrolidin-3-yl (ginistinag)

Immunoglobulin G1 [de-447-lysine], anti-(human tyrosine kinase receptor HER2) (human monoclonal XMT-1519 γ1-chain), disulfide with human monoclonal XMT-1519 κ-chain, dimer, reduced, thioether with 1,1′-[[N5-[(11S)-16-[[5-(aminocarbonyl)-1-[(2E)-4-[6-(aminocarbonyl)-2-[[(4-ethyl-2-methyl-5-oxazolyl)carbonyl]amino]-3H-imidazo[4,5-b]pyridin-3-yl]-2-buten-1-yl]-2-[[(4-ethyl-2-methyl-5-oxazolyl)carbonyl]amino]-1H-benzimidazol-7-yl]oxy]-11-methyl-9,12-dioxo-3,6,13-trioxa-10-azahexadec-1-yl]-N2-[2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)acetyl]-L-α-glutamylglycylglycylglycylglycyl-27-amino-4,7,10,13,16,19,22,25-octaoxaheptacosanoyl-L-glutamoyl]diimino]bis[1-deoxy-D-glucitol]

calotatug ginistinag [INN]

immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], Homo sapiens monoclonal antibody, conjugated on 8 cysteinyl residues to a STING agonist, with a ratio of 1 to 8

External Clinical & Regulatory Resources

Previous UNIIRA7PJF5MAW

Next UNIIRA7ZL8NMY7